HER2 Immunohistochemistry Testing May Not Be Needed in All Solid Tumours By Ogkologos - July 30, 2025 707 0 Facebook Twitter Google+ Pinterest WhatsApp Real-world experience from pan-tumour testing Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR FDA Approves Selpercatinib for Locally Advanced or Metastatic RET Fusion-Positive Solid... September 30, 2022 A new target to slow down ageing and reduce blood cancer... June 29, 2023 Low Incidence of Local Recurrence When Omitting Radiotherapy after Breast-Conserving Surgery... August 22, 2023 Cancer target missed for 55,000 patients over 6 years September 22, 2021 Load more HOT NEWS Cancer in My Community: Expanding Genetic Testing in Thailand In Mouse Study, KRAS-Targeted Drug Shows Potential against Pancreatic Cancer Fewer Women with Ovarian, Breast Cancer Undergo Genetic Testing than Expected FDA Grants Accelerated Approval to Adagrasib for KRAS G12C-Mutated NSCLC
